share_log
Reuters ·  Jan 29 14:22
Os Therapies Agrees to Acquire All Listeria Monotygenes-Based Immuno-Oncology Programs and Ip Assets From Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 407
Write a comment